Illumina Inc. (NASDAQ:ILMN) EVP Omead Ostadan sold 2,378 shares of the business’s stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $160.06, for a total value of $380,622.68. Following the transaction, the executive vice president now directly owns 29,040 shares in the company, valued at $4,648,142.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Omead Ostadan also recently made the following trade(s):
Shares of Illumina Inc. (NASDAQ:ILMN) traded down 0.40% on Thursday, reaching $160.58. The company’s stock had a trading volume of 1,239,686 shares. The company has a market cap of $23.59 billion, a P/E ratio of 53.89 and a beta of 1.16. Illumina Inc. has a 12-month low of $119.37 and a 12-month high of $186.88. The company’s 50 day moving average price is $135.27 and its 200 day moving average price is $151.62.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, November 1st. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.10. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The firm earned $607 million during the quarter, compared to analyst estimates of $628.06 million. During the same quarter in the previous year, the company posted $0.80 earnings per share. The company’s revenue was up 10.4% compared to the same quarter last year. Analysts forecast that Illumina Inc. will post $3.32 EPS for the current fiscal year.
ILMN has been the subject of several recent research reports. Vetr downgraded Illumina from a “buy” rating to a “hold” rating and set a $187.86 price target for the company. in a research note on Monday, October 10th. Cantor Fitzgerald restated a “hold” rating and issued a $155.00 price target on shares of Illumina in a research note on Thursday, November 3rd. BTIG Research restated a “neutral” rating on shares of Illumina in a research note on Wednesday, October 12th. Janney Montgomery Scott restated a “sell” rating and issued a $125.00 price target on shares of Illumina in a research note on Friday, January 6th. Finally, Zacks Investment Research downgraded Illumina from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 19th. Three analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have given a buy rating to the company. Illumina currently has a consensus rating of “Hold” and a consensus price target of $151.96.
A number of large investors have recently modified their holdings of the company. ProVise Management Group LLC increased its position in Illumina by 11.2% in the second quarter. ProVise Management Group LLC now owns 2,292 shares of the life sciences company’s stock valued at $322,000 after buying an additional 230 shares in the last quarter. Prudential Financial Inc. increased its position in Illumina by 0.3% in the third quarter. Prudential Financial Inc. now owns 202,670 shares of the life sciences company’s stock valued at $36,817,000 after buying an additional 655 shares in the last quarter. Gulf International Bank UK Ltd increased its position in Illumina by 0.8% in the third quarter. Gulf International Bank UK Ltd now owns 44,340 shares of the life sciences company’s stock valued at $8,054,000 after buying an additional 350 shares in the last quarter. Westpac Banking Corp bought a new position in Illumina during the third quarter valued at approximately $4,870,000. Finally, KBC Group NV increased its position in Illumina by 56.0% in the third quarter. KBC Group NV now owns 22,325 shares of the life sciences company’s stock valued at $4,056,000 after buying an additional 8,017 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.